Alzheimer’s disease is a debilitating neurodegenerative disease and the most common form of dementia. Symptoms include irritability, confusion, mood swings, language difficulties and memory loss. Cognitive dysfunction becomes more pronounced as the disease progresses, leading to the loss of bodily functions and eventually death.
Alzheimer’s disease is characterized by the presence of amyloid plaques in the brain. Soluble beta-amyloid (Abeta) oligomers are thought to underlie the cognitive deficits associated with Alzheimer’s disease. Cognition Therapeutics therapies pharmacologically compete with Abeta oligomers for critical receptor targets preventing synapse loss and improving memory and their small molecule therapeutics act through molecular targets that have not been previously implicated in Alzheimer’s disease.
Cognition Therapeutics has received a US patent that describes the discovery of several candidate drug molecules which can stop the effects of the brain protein that appears to play a major role in development of Alzheimer's disease. Disease-relevant screening technologyclosely models the pathology of neurodegenerative diseases and novel, high-quality CNS-biased chemical libraries. These platforms can predict behavioral efficacy of candidate drugs in Alzheimer's models. U.S. National Stage Application: No. 13/263,162, entitled "Inhibitors of Cognitive Decline" was filed on October 6, 2011.
CogRx CEO Hank Safferstein said, "The allowance of this patent demonstrates the strength of Cognition Therapeutics's intellectual property and high-level recognition that its technologies are both relevant and of great value to the therapy and ultimate conquering of Alzheimer's disease."
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- This Type Of Baldness By Age 45 Linked To More Aggressive Prostate Cancer
- Life After The 125 GeV Higgs: What Is Left Of Two-Higgs Doublet Models
- Keytruda: FDA Approves Melanoma Drug That Uses Immune System To Fight Cancer
- It's Almost 2015 - So Where Is My Hoverboard?
- How Chicago Almost Ended Up In Wisconsin
- Meet Graphene's Sexy New Cousin Germanene
- No books for you! City Colleges of Chicago Students.
- "When I write of combining Quantum Field Theory and General Relativity, I have my copy of Peskin..."
- "I think it's far from anything like a good compromise. (I can think of many things—even..."
- "Pretty much. It's a compromise between the ebook and the traditional book. I am hoping..."
- "So what is the complaint? There are a lot more partisan cranks framing papers through the politics..."
- "You said that the cases of missing chapters is a problem with the loose leaf version of the book..."
- Dental and nutrition experts call for radical rethink on free sugars intake
- Study shows consumption of high-fat dairy products is associated with a lower risk of developing diabetes
- Study adds to cancer-fighting promise of combined immunotherapy-radiation treatment
- EEG study findings reveal how fear is processed in the brain
- Smithsonian scientists discover tropical tree microbiome in Panama